Revision of the concept of anti-angiogenesis and its applications in tumor treatment

• Published in: Chronic diseases and translational medicine Vol. 3; no. 1; pp. 33 - 40
• Main Authors: Yang, Wen-Hui, Xu, Jun, Mu, Jian-Bing, Xie, Jun
• Format: Journal Article
• Language: English
• Published: United States Elsevier B.V 01.03.2017; Department of Biochemistry and Molecular Biology, Shanxi Medical University, Taiyuan, Shanxi 030001, China; Tumor Hospital of Shanxi Province, Taiyuan, Shanxi 030013, China%Tumor Hospital of Shanxi Province, Taiyuan, Shanxi 030013, China%Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA%Department of Biochemistry and Molecular Biology, Shanxi Medical University, Taiyuan, Shanxi 030001, China; KeAi Publishing; Wiley
• Subjects: Angiogenesis; Anti-angiogenesis; Cancer; Vascular endothelial growth factor; Angiogenesis; Anti-angiogenesis; Vascular endothelial growth factor; Cancer
• ISSN: 2095-882X; 2589-0514; 2589-0514
• DOI: 10.1016/j.cdtm.2017.01.002

Anti-angiogenesis therapy, by blocking formation of new blood vessels in tumors, is the standard-of-care therapy for various cancer types. The classic concept of anti-angiogenesis is expected to turn a tumor into a 'dormant' disease. However, the com-bination of anti-angiogenesis agents with conventional therapeutics has generally produced only modest survival benefits for cancer patients in clinical trials. Therefore, the concept and applications of anti-angiogenesis have evolved dramatically along with lessons learned from recent clinical experience. In this article, we will discuss the revised concept of anti-angiogenesis therapy and the applications of anti-angiogenesis drugs, and focus particularly on how to utilize current anti-angiogenesis agents and develop new approaches to provide more benefits to patients with cancer.